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Summary
Objective: The purpose of this article is to review the current status of drug development as it relates to both molecular targets and clinical
trials for osteoarthritis (OA).
Methods: A review of the literature in the context of currently what is known of the pathophysiology of OA and the learnings from past clinical
trials is provided. Also discussed is the challenge of demonstrating efﬁcacy and clinical beneﬁt for pharmacologic interventions for OA in the
context of current regulatory guidance documents for therapies for the treatment of OA.
Results: There is a large unmet medical need for pharmacologic therapeutic interventions that modify the progression of OA and treat the
symptoms associated with OA.
The development of Disease Modifying OA Drugs (DMOADs) should take into account the current status of therapeutic interventions, as well
as the various tissues that constitute the joint and contribute to joint mechanics, and the symptoms associated with structural changes. There
is much to be learned about the pathophysiology of the joint that is currently poorly understood particularly as it relates to tissues other than
hyaline articular cartilage. Improving our understanding that these tissues play in OA pathophysiology will likely yield treatment breakthroughs.
Recently, tremendous progress has been made in the understanding of pain pathways with an emerging diversity of pain mechanisms and
biology suggesting heterogeneity in pain etiology in OA. A multitude of new targets have been identiﬁed at the level of neuronal transduction/
excitability, conduction, sensitization and transmission with multiple emerging compounds in development.
Conclusions: The development of symptom modifying OA drug is exploding with a plethora of pain pathways being pursued and multiple can-
didates in advanced stages of clinical development. Structure modiﬁcation in OA remains complex with signiﬁcant development challenges.
ª 2009 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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indications of symptom and structure modiﬁcation for oste-
oarthritis (OA) including the review of molecular targets, se-
lected ongoing clinical research, and drug development
challenges and lessons learned from recently completed
studies. A search on the clinicaltrials.gov website generates
about 600 clinical studies for OA; however, this review will
focus on pharmacologic interventions and will not address
research for non-pharmacologic interventions nor regenera-
tive approaches (such as gene or cell therapy) nor provide
an exhaustive review of ongoing OA clinical research.
OA is the most common and costly form of arthritis. The
disease is a slowly, progressive, ultimately degenerative
disorder conﬁned to movable joints. The disease not only
affects articular cartilage but also involves the entire joint in-
cluding the subchondral bone, ligaments, capsule, synovial
membrane and menisci. OA occurs when the equilibrium
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1393unbalanced. Clinically, OA is mainly characterized by joint
pain and functional limitation, however, many subjects
with deﬁnite structural changes consistent with OA remain
asymptomatic.
Existing pharmacological interventions for OA remain in-
sufﬁcient. Current research strategies for therapeutic modu-
lation of OA focus on pain relief (symptom modifying drugs)
or modiﬁcation of the underlying disease (disease modifying
OA drugs or DMOADs). Over the past two decades,
DMOADs have focused on mechanism of actions aimed
at slowing or halting the progression of articular cartilage
destruction or chondroprotection. To date, no DMOADs
are approved by the Food and Drug Administration (FDA)
or European Medicines Agency (EMEA). Pain relief remains
a primary unmet medical need with issues around safety
and tolerability, and enhanced efﬁcacy. In particular, the ef-
fect size of classical non-steroidal anti-inﬂammatory drugs
(NSAIDs) and cyclo-oxygenase-2 inhibitors (COXIBs) re-
mains modest, with relatively narrow therapeutic indices
and relatively poor onsets of action compared to intra-artic-
ular steroid injections. In addition, the elderly OA population
usually presents several comorbidities increasing the risk
for drugedrug interactions and the occurrence of serious
adverse events. Because of these limitations, OA pain is
poorly controlled.
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with many challenges. First, because there are currently no
approved DMOADs on the market, the development path is
unprecedented. Consequently, the primary endpoint for
demonstrating DMOAD efﬁcacy is poorly understood. While
arthroplasty represents the actual end-stage of OA progres-
sion, and has been shown to be a highly cost-effective proce-
dure that dramatically reduces joint pain and disability, its use
as a hard primary endpoint in clinical trials presents multiple
limitations including the variability in the decision to perform
surgery, the patient’s willingness and comorbidities, the
healthcare environment (physician’s/surgeon’s opinion,
healthcare system), socioeconomic disparities, country dis-
crepancies in the time from indication for total joint arthro-
plasty (TJA) to performance of surgery (variability in length
of surgical waiting lists), and relatively low incidence rate of
arthroplasties (i.e., 3% of total knee arthroplasty (TKA) in
the placebo group over 2 years in the Knee OA Structural Ar-
thritis (KOSTAR))1e3. Therefore, alternative clinical end-
points for DMOAD clinical trials have been considered.
From a regulatory perspective, the major licensing authori-
ties (FDA and EMEA and the Committee for Medicinal Prod-
ucts for Human Use [CHMP]) have provided draft guidance
documents for the Pharmaceutical Industry for clinical devel-
opment programs for agents that modify OA structure
(CPMP Points to Consider e Clinical Investigation of Medic-
inal Products Used in the Treatment of OAe 7/98 and FDAe
Clinical Development Programs for Drugs, Devices and Bio-
logical Products Intended for the Treatment of OAe 7/99)4,5.
The suggested regulatory primary endpoint is radiographic
joint space narrowing (JSN). Because the progression of
the disease is slow, minimal and variable within and between
subjects, clinical trials using JSN as a primary endpoint re-
quire the inclusion of large numbers of subjects (several hun-
dred per treatment arm) and long-term treatment period (>1
year). Therefore the size and length of Phase 2 proof of con-
cept (POC) trials aimed at testing for the ﬁrst time the efﬁcacy
of new disease-modifying agents represents a major hurdle.
Both the CHMP and FDA draft guidance documents were
published a decade ago, and are currently undergoing re-
view. The FDA draft guidance review is led by working
groups sponsored by Osteoarthritis Research Society Inter-
national (OARSI). More recently, the FDA published an-
other draft guidance document for the preparation of
Investigational Device Exemptions (IDE) and Investiga-
tional New Drugs (IND) for Products Intended to Repair or
Replace Knee Cartilage (2007). Potential claims for
DMOADs include (1) the delay of the structural progression
of OA characterized by either slowing JSN by at least a pre-
speciﬁed amount; halting progression (improving the X-ray)
or reversing progression (normalizing the X-ray) and (2) the
prevention of OA. The latter presents unresolved assess-
ment issues and study designs capable of properly validat-
ing this claim including the need for the deﬁnition of ‘‘new
OA’’, the target population (i.e., ‘‘normal’’ subjects at risk
for occurrence of OA), the selection of primary and second-
ary endpoints, a signiﬁcantly large number of subjects, long-
term studies, and an extensive safety database.
Both the FDA and CHMP regulatory draft guidance doc-
uments require that a DMOAD agent not only slow JSN
but also result in long-term patient-reported clinical beneﬁt
(e.g., improvement of symptoms and/or function). While
data collected from radiographic studies need to besupported by clinical beneﬁt, it is important to keep in
mind that the comparison of active treatment to placebo
treatment is likely to be in conjunction with a background
of standard of care medications (e.g., NSAIDs/COXIBs),
which may introduce noise in the evaluation of pain relief
and physical function. Separate shorter trials could poten-
tially be used to demonstrate symptom modiﬁcation.
Radiographic JSN (i.e., the loss in Joint Space Width
[JSW]) remains a controversial primary endpoint. Several
factors speak for its clinical relevance. JSW represents the
joint interbone distance which at the level of the knee not
only includes the articular cartilage and its associated degen-
erative changes but also the menisci and meniscal lesions/
extrusions related to OA. Various methods of quantitative
measurements of JSW have been developed and validated
over the past 15 years including minimum JSW, mean
JSW, and JSW at ﬁxed locations. Recently, annual rates of
JSN and its variability have been well-characterized in vari-
ous studies enabling the powering of clinical trials6,7. How-
ever, despite state of the art standardization of radiographic
protocols to reduce the variability related to changes in joint
repositioning, the average JSN annual rate remains small
(w0.1e0.2 mm/year) requiring large and long clinical trials.
In addition, and in contrast to other imaging techniques like
magnetic resonance images (MRI) for example that are ac-
quired in the supine position, knee radiographs are taken in
the weight-bearing position providing information on the al-
tered mechanical properties of both the articular cartilage
and menisci related to OA. Most importantly, the predictive
value of JSN was reported in a multicentre, prospective, lon-
gitudinal, 5-year follow-up study, where JSN was shown to
predict the subsequent requirement for arthroplasty8.
However, JSN may not be considered entirely clinically
relevant as a primary endpoint for DMOAD efﬁcacy. OA is
a disease of the whole joint not just articular cartilage and
meniscus. First, OA affects all the joint tissues including
the subchondral bone, synovium, ligaments, and capsule.
While most mechanism of actions of new chemical entities
are unlikely to affect only the cartilage and/or meniscal tis-
sues, capturing potential early beneﬁcial changes in other
joint tissues using more advanced imaging technologies
than radiographs (e.g., MRI) may enable the development
of new drugs9. Second, JSN is known to be insensitive to
early OA changes in cartilage and meniscus, therefore
knees with moderate to severe OA (Kellgren and Lawrence
Grade [KLG] 3) are selected for clinical trials to ensure dis-
ease progression measurement. However, KLG 3 knees
may already represent a late stage of the disease with ad-
vanced molecular and biomechanical changes and it may
be too late for any pharmacological intervention to alter
the course of the disease. JSN is also unlikely to be an ap-
propriate endpoint for measuring the efﬁcacy of cartilage re-
pair products. Magnetic resonance imaging and
arthroscopy should provide better information for such ther-
apies. Finally, one major limitation has been the paucity of
reports demonstrating a correlation of JSN with symptoms,
when in fact; the majority of OA literature reports a lack of
correlation of JSN with severity of symptoms. These limita-
tions have stimulated research for other imaging technolo-
gies to detect more sensitively OA progression and
enabling shorter and smaller POC trials, however, currently
no imaging alternative has demonstrated greater sensitivity
to change than JSN10.
As yet with these thresholds for detecting clinically mean-
ingful effects, no disease-modifying efﬁcacy has been con-
vincingly demonstrated for any of the existing
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progression without symptomatic beneﬁt suggesting that
simply slowing progression may not be sufﬁcient to lead
to symptom improvement. Table I summarizes recently
completed DMOAD trials with both pharmaceutical and
neutraceutical agents. Even though none of those clinical
trials have led to the successful registration of a DMOAD,
researchers have learned important lessons which should
be carefully considered when designing future DMOAD
studies.
First and foremost, because of chronic administration in
a population withmultiple comorbidities, DMOAD candidates
must demonstrate pristine safety. The best illustration of this
safety requirement comes from the development of matrix
metalloproteinase (MMP) inhibitors. While a very attractive
and relevant target, the development of MMP inhibitors has
been hampered by the occurrence of a musculo-skeletal
syndrome (MSS), a painful joint stiffening musculoskeletal
side effect similar to Dupuytren’s disease and adhesive cap-
sulitis (frozen shoulder) apparently related to the lack of se-
lectivity and relative broad-spectrumMMP inhibition of these
compounds11. There are, however, still someMMP inhibitors
with more selective speciﬁcity proﬁles in preclinical or early
clinical development. Several of these candidates are spe-
ciﬁc for MMP-13, which is overexpressed by OA cartilage,
and have minimal effects on MMP-1, which has been impli-
cated in the development of MSS12.
The results of 2, 2-year Phase 3 Risedronate DMOAD
clinical trials have also taught us that selecting an OA pop-
ulation at risk to progress during the course of the treatment
period is key to avoid failed clinical studies. In both Risedr-
onate studies little to no progression was detected in the
placebo groups thereby masking the detection of a potential
treatment effect1. As in rheumatoid arthritis clinical trials,
a small number of OA patients drive mean changes, while
most patients experience little to no progression during
the study. It is therefore critically important to recruit at-
risk patients to progress during the course of the study.
Conversely, in the Doxycycline trial where the study popula-
tion was enriched for obese women with knee OA, progres-
sion of JSN was detected as early as 16 months6. As
indicated above, if JSN is to be used as a primary endpoint,
selecting patients with moderate to severe disease (KLG 3)
appears to be the key to detecting progression as they are
more likely to progress during the course of the study. How-
ever, KLG 3 subjects also may be more likely to exhibit
marked aberrant mechanics, for example, mechanics re-
lated to signiﬁcant varus or valgus malalignment. Therefore,
the selection of a speciﬁc target population is complex and
may have a major impact on the Screen Failure rate (i.e.,
Risedronate trials had a SF rate of 73%) and consequently
on the cost of a DMOAD clinical trial.
Designing trials with co-primary endpoints for symptoms
and structure beneﬁt assessments represent a signiﬁcant
challenge. A systematic placebo response has been identi-
ﬁed in long-term OA studies, starting as early as 3e6
months. The origin of the placebo response is unclear
and it may be related to multiple factors including expecta-
tional bias from patients, pain questionnaires unable to dis-
cern the effect of low levels of background pain, noise from
background pain medications allowing for subject retention,
and/or the lack of washout periods before pain
assessments.
A major unanswered question is what constitutes clini-
cally meaningfulness for DMOAD activity in particular as it
relates to slowing JSN. While OA disease progresses
slowly (i.e., 20e40 years from incidence of OA to total jointreplacement (TJR)) and long-term studies are likely to be
required to demonstrate both long-term beneﬁt and safety,
there is a major need for more responsive outcome mea-
sures for both symptom and structure modifying agents.
Biomarkers (i.e., imaging and biochemical) for early assess-
ment of efﬁcacy are key to evaluate the efﬁcacy of com-
pounds in Phase 1 proof of mechanism and/or Phase 2
POC trials. Researchers need to continue to focus on de-
veloping and qualifying biomarkers to enable the develop-
ment of DMOADs. Without biomarkers, developing
DMOADs will continue to be a major challenge with fewer
and fewer pharmaceutical companies pursuing the develop-
ment of agents for preserving the structure of joints affected
by OA. An attractive alternative to biomarkers is the demon-
stration of an effect on OA signs and symptoms early in de-
velopment. The development of compounds that treat the
signs and symptoms of OA requires demonstration of safety
in long-term studies enabling the concomitant assessment
of efﬁcacy on structural changes related to OA. This con-
cept can be easily pursued for mechanisms of action having
a direct effect on molecular pathways related to pain. How-
ever, among the molecular targets being studied, few are
expected to modulate directly pain mechanisms.
Another important learning from drug development is the
need for preclinical models that are more predictive of hu-
man OA progression. Most animal models of OA are surgi-
cal joint instability models (e.g., partial or radical
meniscectomy, anterior cruciate ligament models). While
these models reproduce the characteristic degenerative
joint changes observed in human OA, the development of
these changes in animals in terms of speed and magnitude
is signiﬁcantly accelerated compared to those in humans. It
is likely because of modest results in animal models that the
development of many agents is being halted and that those
never enter Clinical development.
It may seem ironic that over the past two decades drug
development has focused research on articular cartilage
considering OA changes affect the whole joint and that nor-
mal articular cartilage is both aneural and avascular, and
therefore not regarded as a major source of pain. A recent
report however, demonstrated neurovascular invasion at
the osteochondral junction and in osteophytes in OA13. In
addition, cartilage breakdown products lead to synovitis,
and promote meniscal and subchondral bone changes.
Therefore, agents aiming at exclusively restoring articular
cartilage can be regarded as having little chance to provide
long-term clinical beneﬁt. However, it is unlikely that new
chemical entities will affect cartilage only since molecular
pathways of tissue degeneration associated with OA ap-
pear to be similar in other joint tissues (i.e., meniscus, syno-
vium, bone)14e16.
In order to avoid most of the limitations related to JSN,
a special interest group sponsored by OMERACTeOARSI
proposed the alternative of changing the outcome measure
of ‘‘time to TJR’’ to ‘‘time to fulﬁllment of criteria for TJR’’ or
more commonly the ‘‘virtual joint endpoint’’17. The criteria
for the virtual joint endpoint will include the three universal
domains of pain, physical function and structure which are
to be assembled as a composite index. New instruments
to assess the domains of pain and function have been de-
veloped for both the hip and knee joints18,19. For the struc-
ture domain, a progressor is deﬁned as an absolute change
in JSW over a predeﬁned threshold based on the evaluation
of the measurement error of the radiological technique20.
The validation of the virtual joint endpoint is ongoing in
a large worldwide multicenter study of patients requiring
hip or knee TJR.
Table I
Recently completed DMOAD clinical trials
Drug (sponsor) Study design/joint/population Size/duration/arms Primary endpoint Outcome
Risedronate (P&G) BRISK study57 Phase 2
RCCT in knee OA patients
e General OA pop.
Nw95/arm e 1 yr, 5 and
15 mg QD risedronate
JSNþWOMAC/PGA No signiﬁcant
difference from placebo
Risedronate (P&G) KOSTAR study1 2 Phase 3
RCCTs in knee OA patients
e General OA pop.
Nw305/arm e 2 yr e 5
& 15 mg QD, 35 mg/wk (EU)
& 50 mg/wk (NA) risedronate
JSNþWOMAC/PGA No signiﬁcant difference
from placebo
MMP inh (P&G) Phase 2 e RCCT in patients
with knee OA58 e General
OA population
N¼ 75/arm 1 yr e 25e200 mg
BID PG-116800 (MMP-1, 7
sparing MMP-2, 3, 8, 9, 13 & 14 inh.)
JSNþWOMAC/PGA No signiﬁcant difference
from placebo
Doxycycline (NIH) RCCT in patients with knee
OA6 e obese women
Nw215/arm e 2.5 yr, 100 mg
BID doxycycline
JSN 30% reduction in JSN
compared to placebo
Licofelone (Merckle Gmbh) RCCT in patients with knee
OA59 e At least one of three
RFs: BMI> 30, female,
Heberden’s nodes
Nw150/arm e 2-yr, 200 mg BID
licofelone vs naproxen 500 mg BID
Cartilage volume loss Signiﬁcant difference
from naproxen
Glucosamine sulfate (Rottapharm) Two RCCTs in patients with
knee OA60,61 e General
OA population
N¼ 106/arm e 3 yr, 1500 mg GS QD JSN Signiﬁcant difference
from placebo
GAIT (NIH) RCCT in patients with knee
OA62 e General OA population
Nw315/arm e 2 yr, 500 mgG TID;
400 mg CS TID; Combo GþCS TID;
Celebrex 200 mg
JSN No signiﬁcant difference
from placebo
Diacerein (Negma) ECHODIAH study3 RCCT in
patients with hip OA
N¼ 260/arm e 3 yr, 50 mg diacerein BID JSN Signiﬁcant difference
from placebo in completer
analysis but not ITT
Chondroitin 4&6 sulfate (IBSA) STOPP study63 RCCT in patients
with knee OA e General
OA population
Nw310/arm e 2 yr, 800 mg QD CS JSN Signiﬁcant difference
from placebo
P&G: Proctor and Gamble; IBSA: Institut Biochimique Socie´te´ Anonyme; BRISK: British study of Risedronate in Structure and symptoms of Knee OA; ECHODIAH: Evaluation of the CHOn-
dromodulating effect of DIAcerein in osteoarthritis of the Hip; STOPP: STudy on Osteoarthritis Progression Prevention; RCCT: Randomized Controlled Clinical Trial; RFs: Risk Factors; BMI:
Body Mass Index; pop.: population; yr: year; QD: once a day; BID: twice a day; TID: three times a day; GS: Glucosamine Sulfate; CS: Chondroitin Sulfate; Combo: combination; PGA: Patient
Global Assessment of Arthritis; ITT: Intent to Treat Analysis.
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Table II
Current targets, mechanism of actions and route of administration
Anti-Catabolics Anabolics
Systemic
(Oral, SC, IV)
Calcitonin
iNOS inhibitors
Aggrecanase inhibitors
MMP-13 inhibitors N.A.
Cathepsin K inhibitors
Anti-IL-1b
TNF-a blockers
Local
(Intra-Articular)
Lubricin
TIMP-3
OP-1 FGF-18
Anti-IL-1b OP-1
TNF-a blockers Mesenchymal
stem cells
MMP-13 inhibitors
SC: sub-cutaneous; IV: intra-venous; IL: interleukin; TNF: tumor
necrosis factor; N.A.: not applicable.
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nisms of action. Anti-catabolic agents aim at slowing or halt-
ing the progression of OA, while anabolic agents aim at
inducing cartilage re-growth. Routes of administration in-
clude both oral and intra-articular injection. Table II summa-
rizes the targets currently pursued. Multiple mechanisms of
action currently under clinical development are summarized
in Table III.
Calcitonin, a thyroid hormone known to lower the Ca and P
blood levels, inhibits osteoclast bone removal and promotes
osteoblast bone formation and is indicated for the treatment
of hypercalcemia, the prevention of osteoporosis in post-
menopausal women as well as Paget’s disease. Preclinical
evidence in the Pond-Nuki OA model indicated that Calcito-
nin reduces urinary deoxyPYD crosslinks and the severity of
articular cartilage lesions21. The hypothesis for the develop-
ment of Calcitonin as a DMOAD is related to the fact that
bone changes are key to OA development and progression.
Oral treatment with Calcitonin may preserve healthy bone,
prevent osteophyte changes and slow weaker repair bone
deposition in the subchondral region, and maintain normal
contour and shape of the articular surfaces.
The role of inducible nitric oxide synthase (iNOS) as a me-
diator of cartilage and meniscal destruction has been exten-
sively reported and suggests that iNOS inhibitors mayTable I
Current molecular targets in
Target (Sponsor) Study design
Oral salmon calcitonin
(Nordic Biosciences/Novartis)
Two Phase 3 RCCTs in knee OA
iNOS inhibitor (Pﬁzer) Phase 2b/3 RCCT in overweight
and obese knee OA patients
Piascledine-ASU
(Expanscience)
RCCT in hip OA
Vitamin D (NIAMS) RCCT in knee OA
FGF-18 (Merck Serono) Phase 2 RCCT in knee OA
Aggrecanase inhibitor
(Wyeth)
Phase 1 RCCT in knee OA
OP-1 (Stryker) Phase 1 RCCT in knee OA,
SD escalation, safety
ASU: Avocado soybean unsaponiﬁables.provide disease-modifying chondroprotective activity in hu-
man OA. The expression of iNOS in OA joint tissues, is in-
duced by cytokines, and/or other pathologic stresses, and
generates high, sustained concentrations of nitric oxide
(NO) resulting in NO-derived metabolites, particularly the
damaging radical peroxynitrite, eliciting cytotoxicity and tis-
sue damage in turn producing alterations in normal physio-
logical function. Selective inhibitors of iNOS have been
shown to markedly decrease the progression of articular de-
generation in models of experimental OA with reduction in
the size of cartilage lesions and the size and number of os-
teophytes. The decreases in the degenerative changes in
the OA joint correlated with reductions in biochemical medi-
ators of tissue damage, including prostaglandins, metallo-
proteinases, and IL-1b22e24. In addition, the presence of
iNOS, NO production, and 3-nitrotyrosine (a marker for per-
oxynitrite-mediated damage) have also been correlated with
the rate of apoptosis in OA chondrocytes and meniscal ﬁ-
brochondrocytes in rabbit models of OA, also suggesting
that iNOS plays a role in cell death and cartilage and menis-
cus degradation25e27. Finally, iNOS knockout mice have
a greatly reduced incidence and severity of joint deteriora-
tion in acute and chronic models of cartilage degradation28.
The biomechanical properties or normal articular cartilage
depend on intact collagen network and high proteoglycan
(PRG) content. Collagenases cleave type II collagen at spe-
ciﬁc sites generating neoepitopes than can be measured in
the synovial ﬂuid (SF) using speciﬁc antibodies29,30. In par-
ticular, MMP-13, the dominant collagenase expressed in
human OA cartilage, is signiﬁcantly more active against
type II collagen than any other collagenase. Modest overex-
pression via an inducible transgene causes an OA-like phe-
notype31. While the ﬁrst clinical trials for MMP inhibitors
were conducted more than two decades ago, the develop-
ment of these class of agents has been hampered by signif-
icant safety issues including those related to the
development of MSS. However, more recently, highly spe-
ciﬁc inhibitors of MMP-13 have been shown to protect artic-
ular cartilage in OA experimental models in multiple species
with protective effects comparable to those of broad-spec-
trum MMP inhibitors. Multiple MMP-13 speciﬁc inhibitors
are in early phase development.
The loss of aggrecan, the major PRG of articular carti-
lage, is mainly driven by aggrecanases. Aggrecanase-1
(or ADAMTS-4 (A Disintegrin and Metalloproteinase with
ThromboSpondin motifs)) and aggrecanase-2 (ADAMTS-5)
cleave aggrecan at speciﬁc sites releasing neoepitopes thatII
clinical development
Duration Primary endpoints
2 years Radiographic JSN
WOMAC
2 years Radiographic JSN
3 years Radiographic JSN
2 years MRI cartilage volume loss
1 year MRI cartilage thickness loss
4 weeks SF biochemical markers
24 weeks Safety, secondary endpoints: signs
and symptoms, biomarkers, X-ray/MRI
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The relative contribution of individual ADAMTS proteases
to cartilage destruction during OA has not been resolved.
In ADAMTS-5 knockout (KO) mice in which OA was surgi-
cally induced through joint instability, a signiﬁcant reduction
in the severity of cartilage destruction was observed com-
pared with wild-type (WT) mice34. Similarly, dual
ADAMTS-4 and ADAMTS-5 KO mice exhibited signiﬁcant
reduction in the severity of experimental murine OA35. In
addition, both KO mice were phenotypically indistinguish-
able from WT mice suggesting that aggrecanase inhibitors
may be a reasonable therapeutic strategy for OA36. Aggre-
canase inhibitors are in early clinical development.
The tissue inhibitors of metalloproteinases (TIMPs) are
endogenous inhibitors of the MMPs37. TIMP-3 is the endog-
enous inhibitor of both ADAMTS-4 and -5. Only TIMP-3 is
capable of blocking aggrecanase activity; TIMP-1, -2 and
-4 are inactive against ADAMTS-4 and -5. TIMP-3 also in-
hibits MMP-13 and TACE. TIMP-3 KO mice spontaneously
lose their articular cartilage38. Intra-articular injections of
full-length or N-domain TIMP-3 appear to protect cartilage
from OA degeneration in the rat MMT model. TIMP-3 KO
mice appear phenotypically normal. Taken together, these
data suggest TIMP-3 as an attractive target for DMOADs.
Several compounds are in preclinical development.
In recent years, the function of osteogenic protein-1 (OP-1)
or BMP-7 in cartilage homeostasis and repair has been better
characterized39,40. In vitro and in vivo studies have shown
that OP-1 is a unique growth factor in that it exhibits both
strong anabolic activity (e.g., stimulation of the expression
of type II collagen, aggrecan, hyaluronan, CD-44, IGF-1)
and anti-catabolic properties (e.g., inhibition of proteinases
including aggrecanase, MMP-3, MMP-13 and cytokines
such as IL-6) suggestingOP-1 as a therapeutic target of inter-
est in cartilage repair. In experimentalmodels ofOA including
the sheep impaction model or the rabbit anterior cruciate lig-
ament (ACL) transaction model, intra-articular injection of
OP-1 inhibited the progression of OA. In addition, OP-1 has
been reported to have the ability to repair cartilage in vivo in
various models of articular cartilage degradation, including
focal osteochondral and chondral defects and OA, as well
as models of degeneration in intervertebral disc cartilage.
Fibroblast growth factor-18 (FGF-18) is a novel growth
factor that may play a prominent role in chondrogenesis
and osteogenesis during skeletal development and
growth41. FGF-18 has been reported to have signiﬁcant an-
abolic effects on cartilage. In a rat meniscal tear model of
OA, fgf-18 was injected intra-articularly bi-weekly for 3
weeks. FGF-18 induced dose-dependent increases in carti-
lage thickness of the tibial plateau in relation to new carti-
lage formation at the articular surface and the joint
periphery resulting in signiﬁcant reductions in cartilage de-
generation scores. The highest dose of FGF-18 was asso-
ciated with an increase in both chondrophyte size and
subchondral bone remodeling42.
Lubricin or superﬁcial zone protein (SZP) or PRG4, is a se-
creted, cytoprotective glycoprotein that contributes to the
boundary lubrication properties necessary for low friction
levels at articular cartilage surfaces43. Alteration of lubricin
function has been suggested as an adverse contributing fac-
tor in thedevelopment ofOA. In particular, theexpressionand
amount of secreted lubricin has been shown to signiﬁcantly
reduced by exposure of synoviocytes, chondrocytes and car-
tilage explants to IL-1b and TNF-a, while administration of
transformng growth factor (TGF)-b signiﬁcantly upregulated
lubricin synthesis, secretion and cartilage boundary
association.Symptom modifying drugs
Despite numerous drugs on the market approved to treat
the signs and symptoms of OA, pain relief remains a chal-
lenging clinical entity to treat. The pain in OA is multifaceted
and is likely the result of the interplay of multiple factors in-
cluding disease status, environmental, gender, genetics
and personality attributes. However, the elative contribution
of these factors varies across the OA population, which cre-
ates opportunities for individualized pharmacological treat-
ment approaches. In the past decade, tremendous
progress has been made in the understanding of pain path-
ways with an emerging diversity of pain mechanisms and
biology suggesting heterogeneity in pain etiology in OA. A
multitude of new targets have been identiﬁed at the level
of neuronal transduction/excitability, conduction, sensitiza-
tion and transmission. There are about 20 new molecular
entities currently being pursued by the Pharmaceutical In-
dustry with some already in late stage development. Emerg-
ing compounds in development will be reviewed brieﬂy.
Tapentadol co-developed by Grunenthal and Johnson &
Johnson Pharmaceutical Research and Development is
a centrally acting analgesic with a unique dual mode of ac-
tion as an agonist at the m-opioid receptor and as a norepi-
nephrine reuptake inhibitor. m-opioid agonists bind to m-
opioid receptors in the CNS, modify sensory and affective
(mood) aspects of pain, inhibit the transmission of pain at
the spinal cord and affect activity at parts of the brain that
control the perception of pain. Norepinephrine reuptake in-
hibitors are a type of increase the level of norepinephrine
in the CNS by inhibiting its re-absorption into nerve cells,
giving analgesic properties. Tapentadol’s dual mode of ac-
tion provides analgesia at similar levels of more potent nar-
cotic analgesics with a more tolerable side effect proﬁle. It is
currently undergoing regulatory review for approval.
A new target for inﬂammatory pain known as vanilloid re-
ceptor 1 (transient receptor potential vanilloid (TRPV1)) is be-
ing investigated. It belongs to a large family of 28 ligand gated
ion channels with diverse functions. A subset of them
(TRPV1, TRPV, TRPV3, TRPV4, TRPM8, TRPA1) is ex-
pressed on sensory neurons and involved in pain transduc-
tion. TRPV1 (vanilloid) was discovered in 1997 from the
activity of capsaicin, the active component of hot chili pep-
pers44. Capsaicin selectively activates TRPV1, a receptor
found in pain-sensing nerves. TRPV1 is expressed in the dor-
sal root ganglion (DRG) neurons. Loss of TRPV1 responsive
nerves or loss of TRPV1 expression causes decreased pain
sensitivity during inﬂammation. Multiple compounds target-
ing TRPV1 are currently in Phase 2 development.
Selective sodium ion channel modulators are being devel-
oped with several compounds in Phase 2 clinical trials. Volt-
age-gated sodium ion channels play a critical role in
transduction and conduction of pain stimuli45. Multiple sub-
types with distinct biophysical properties and expression pat-
terns exist. Thenociceptive neurons in theDRGexpressNaV
1.7, NaV 1.8, NaV 1.9 andNaV 1.3. Interesting cases of Con-
genital Insensitivity toPain havebeen reported like that of Ed-
ward H Gibson called ‘‘The human Pin cushion’’ in relation to
a mutation in Nav 1.7. Selective blockade of individual sub-
types should enhance the efﬁcacy/safety ratio.
Joint tissue damage and inﬂammation lead to the activa-
tion of proteolytic kallikreins. Kallikreins generate kinins in-
cluding Bradykinin. Bradykinin is the initial mediator of
inﬂammation that causes nociceptor activation and sensiti-
zation via two G-protein coupled receptors, B1 and B2.
While B2 is constitutively expressed, B1 expression occurs
following tissue damage and inﬂammatory signals including
1399Osteoarthritis and Cartilage Vol. 17, No. 11nerve growth factor (NGF) and cytokines such as IL-1b and
TNF-a. Kinins cause a cascade of secondary effects includ-
ing the production of prostanoids and NO, the phosphoryla-
tion of signaling proteins (e.g., PLA2, protein kinase C
(PKC)) and the sensitization of sensory transducers such
as TRPV1. Both B1 and B2 KO mice exhibit hypoalgesia
in response to painful stimuli46,47. Several B1 and B2 antag-
onists are currently in early clinical development. Injections
of Icatibant (Sanoﬁ-Aventis), a potent, speciﬁc, long-acting
B2 antagonist showed reduced pain intensity at rest and
during activity in patients with symptomatic OA, however,
no signiﬁcant effects were observed on inﬂammation as
measured by power Doppler ultrasound (US), contrast-en-
hanced (CE) US and CE-MRI48.
Pain modulation effects of cannabinoids are mediated
through CB1 and CB2 G-protein coupled receptors49. The
CB1 receptors are widely distributed in the CNS and periph-
eral sensory neurons and tissues, whereas the CB2 recep-
tors are predominantly found on immune tissues and
keratinocytes with some expression in sensory and brain-
stem neurons. Both receptors are constitutively expressed
by chondrocytes. Side effects such as vertigo, euphoria,
dizziness and sedation, are likely to be mediated by central
CB1 receptors and limit their therapeutic application and are
unlikely to be tolerable in OA patients. Therefore, to reduce
the risk of abuse liability and to preclude CB1 mediated cen-
tral side effects, selective CB2, peripherally restricted CB1
or dual CB1/CB2 agonists are under development. In addi-
tion, the endocannabinoid system offers an alternate point
for pharmaceutical intervention and opportunities for a com-
bined strategy for analgesia. The fatty acid amide hydrolysis
(FAAH) pathway presents a major degradation pathway for
endogenous cannabinoids whereas the addition of FAAH
inhibitors will prevent endocannabinoid breakdown and
may provide an improved safety proﬁle.
Joint inﬂammatory mediators play an important role in
mediating pain in OA. Synovial reaction and fat pad inﬂam-
mation (e.g., adipokines) are frequently present in OA and
may correlate with pain and other clinical outcomes50.
The synovium is densely innervated by small-diameter sen-
sory nerve ﬁbers51. SF mediators including TNF-a, IL-6, IL-
1b, calcitonin gene related peptide (CGRP), Substance P,
vasoactive intestinal peptide (VIP), NGF, PGE2, Glutamate,
5-HT have been shown to be elevated in OA. The pro-in-
ﬂammatory cytokines, IL-1b and TNF-a excite and sensitize
nociceptors and contribute in vivo to behavioral signs of in-
ﬂammatory hyperalgesia through NGF for example52,53.
Moreover, cytokines enhance the release of PGE2, iNOS,
and histamine from chondrocytes, meniscal cells and
mast cells, which in turn can (indirectly) increase the sensi-
tization of nociceptors.
NGF exerts its action through two types of receptors: high-
afﬁnity tyrosine kinase A receptor (trkA) and low-afﬁnity p75
receptor. Both NGF and its receptors are expressed in syno-
vial, meniscal and articular cartilage tissues suggesting that
they could be involved in joint physiopathology and OA54,55.
NGFactivatesmast cells, and sensitizes and phosphorylates
TRPV1 receptors increasing transport to cell surface and
channel activity. NGF also increases expression of proteins
that further sensitize these neurons including the three major
mitogen-activated protein kinase (MAPK) families (i.e., ERK,
p38 and c-Jun). Pﬁzer’s tanezumab (RN624), is a humanized
monoclonal antibody against NGF. In two recently completed
randomized, placebo-controlled, double blind studies in pa-
tients with chronic OA pain, a single dose (SD) of tanezumab
showed signiﬁcant improvement in WOMAC scores com-
pared to placebo56.Duloxetine (Eli Lilly), a potent, selective and relatively bal-
anced serotonin (5-HT) and norepinephrine (NE) reuptake in-
hibitor (SNRI) is indicated for major depressive disorder,
general anxiety disorder, diabetic peripheral neuropathy and
ﬁbromyalgia. Recently, duloxetine 60/120 mg/day improved
painsymptomsandpatient-reportedoutcomesover13weeks
of treatment inpatientswithOAof theknee relative toplacebo.
Conclusions
The development of symptommodifying OA drug is explod-
ing with a plethora of pain pathways being pursued and multi-
ple candidates in advanced stages of clinical development. In
contrast, structure modiﬁcation presents signiﬁcant develop-
ment challenges with a totally unprecedented development
path, the need for both more sensitive outcome measures,
and the characterization of clinically meaningful improve-
ments. Given the difﬁculties associated with the development
ofDMOADs, it is critically important that theScientiﬁcCommu-
nity encompassing scientists from both Academia and the
Pharmaceutical Industry conceptualize a more collaborative
approach in diseasemodiﬁcation research if weare not to con-
front the extreme of total abandonment of the ﬁeld. The risk of
the total extinction of an area ofOA research is knocking at the
door and should be taken seriously. The future ofOA research
which requires huge expenditures of dollars into unprece-
dented pathways is likely to become rapidly a thing of the
past but collaborative efforts of sharing resources (scientiﬁc
knowledge, people, funding) across companies and Acade-
mia may be the solution to ebb the ﬂow of extinction.Conﬂict of interest
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